Last reviewed · How we verify
NCT04121416
Comparison of Effects of Oxycodone and Sufentanil on Cardiovascular Stress Induced by Tracheal Intubation in the Patients With Coronary Heart Disease Undergoing Major Noncardiac Surgery
NA trial testing Oxycodone 10mg in Cardiovascular in 50 participants. Completed in 19 September 2019.
31 August 2019
Quick facts
| Lead sponsor | Shengjing Hospital |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | quadruple |
| Primary purpose | other |
| Enrollment | 50 |
| Start date | 1 April 2019 |
| Primary completion | 31 August 2019 |
| Estimated completion | 19 September 2019 |
| Sites | 1 location across China |
Drugs / interventions tested
- Oxycodone 10mg — full drug profile →
- Sufentanil (SUFENTANIL) — full drug profile →
Conditions studied
- Cardiovascular — all drugs for Cardiovascular →
Sponsor
Shengjing Hospital
Who can join
Adults 60 to 85, female only, with Cardiovascular. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
To evaluate the effect of oxycodone and sufentanil in preventing cardiovascular responses to tracheal intubation in the patients with coronary heart disease (CHD).
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT04121416
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Oxycodone 10mg
Trials testing the same drug.
- NCT05598905 — Combined Effect of Pregabalin and Oxycodone, and Lacosamide and Oxycodone, on Breathing · Phase 4 · completed
- NCT06142591 — Oxycodone (10, 20 mg) in a Postoperative Dressing · Phase 4 · completed
Other recruiting trials for Cardiovascular
Currently open trials in the same condition.
- NCT06975111 — Focusing on the Menopausal Transition to Improve Mid-Life Women's Health · Phase 2, PHASE3 · recruiting
- NCT07382752 — Decoupling Immunotherapy Toxicity and Cancer Response · recruiting
- NCT07396857 — The Role of EDHFs on Blood Pressure Following a Bout of Prolonged Sitting · NA · recruiting
- NCT07179107 — Adequate Hydration and Health Outcomes · NA · recruiting
- NCT06840756 — Effects of Donor-recipient Sex-matched Blood Transfusion on Patient Outcomes · Phase 4 · recruiting
Other Shengjing Hospital trials
Trials by the same sponsor.
- NCT07484763 — Predicting Recurrence in HR+/HER2- Early Breast Cancer · not yet recruiting
- NCT07497191 — AMH Dynamic Changes to Predict Ovarian Reserve in Perimenopausal Breast Cancer · not yet recruiting
- NCT07320599 — Neuroendoscopic Surgery With Ommaya Reservoir Implantation vs. Burr Hole Drainage for Infantile Postmeningitis Subdural · not yet recruiting
- NCT07153783 — Interventional AI-Human Collaboration for Liver Tumor Diagnosis · NA · completed
- NCT07101614 — A Randomized Study of JS004 and Toripalimab Combined With Chemotherapy vs Toripalimab Combined With Chemotherapy vs Chem · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04121416 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Shengjing Hospital
- Last refreshed: 9 October 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04121416.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing